v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash $ 186,014 $ 88,857
Restricted cash 20,000 20,000
Accounts receivable 2,058 51,324
Prepaid and other current assets 1,252,670 1,038,071
Total current assets 1,460,742 1,198,252
In process R&D 1,101,760 1,101,760
Goodwill, net of impairment 2,788,230 2,788,230
Investment in equity securities 1,400,000
Investment in GMP Bio at fair value 388,000,000 388,000,000
Total assets 394,750,732 393,088,242
Current liabilities:    
Accounts payable and accrued liabilities 2,554,999 2,571,123
Contingent consideration 2,625,000 2,625,000
Derivative liability on notes 337,256 350,044
Total current liabilities 17,906,958 18,143,278
Convertible long-term debt, net of costs 1,854,395 1,663,405
Deferred income tax liability 111,550,000 111,550,000
Total liabilities 131,311,353 131,356,683
Commitments and contingencies (Note 15)
Stockholders’ equity:    
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 50,900 and 24,388 issued and outstanding, respectively 509 244
Common stock, $0.01 par value; 750,000,000 shares authorized; 457,012,796 and 442,596,856 issued and outstanding, respectively 4,570,125 4,425,968
Additional paid-in capital 50,556,882 47,095,219
Accumulated equity 209,433,535 211,239,164
Total Oncotelic Therapeutics, Inc. stockholders’ equity 264,561,051 262,760,595
Non-controlling interests (1,121,672) (1,029,036)
Total stockholders’ equity 263,439,379 261,731,559
Total liabilities and stockholders’ equity 394,750,732 393,088,242
Related Party [Member]    
Current liabilities:    
Accounts payable to related party 349,138 348,111
Convertible debt and short-term debt, net of costs 4,114,684 4,023,331
Nonrelated Party [Member]    
Current liabilities:    
Convertible debt and short-term debt, net of costs $ 7,925,881 $ 8,225,669